Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript

Carl Zeiss Meditec Q2 Earnings Call Highlights

06:10am, Tuesday, 12'th May 2026
Carl Zeiss Meditec ETR: AFX reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management po
Carl Zeiss Meditec AG (OTCMKTS:CZMWY - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totaling 5,102 shares, a growth of 89
Carl Zeiss Meditec AG is rated a "Buy" despite recent operational weakness and geopolitical headwinds, especially in Asia-Pacific and North America. Sales declined 4.8% in Q1, with margin compression
Shares of Carl Zeiss Meditec AG (OTCMKTS:CZMWY - Get Free Report) have been assigned a consensus rating of "Hold" from the six ratings firms that are covering the stock, MarketBeat.com reports. One re
Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript
Carl Zeiss Meditec is rated a 'Strong Buy' with higher share price target, reflecting significant undervaluation and robust fundamentals. The company achieved over €2.2B in revenue (+7.5% YoY), stro
Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Discusses CEO Transition and Management Continuity Strategy Following Code of Conduct Investigation Transcript
Carl Zeiss Meditec remains a high-quality medtech leader with strong moats in ophthalmic and microsurgery, despite recent margin pressures and Chinese market headwinds. Recent 6M25 results show encour
Carl Zeiss Meditec AG (OTCPK:CZMWF) Q2 2025 Earnings Conference Call May 13, 2025 4:30 AM ET Company Participants Sebastian Frericks - Director of Investor Relations Markus Weber - President and Chief
Carl Zeiss Meditec remains a "Buy" despite tariff concerns, with a revised price target of €110/share, reflecting geopolitical uncertainties and potential impacts on US-based revenues. The company s

Carl Zeiss: Why I Am So Positive

03:01am, Wednesday, 04'th Dec 2024
Carl Zeiss Meditec is a high-quality MedTech company with a strong market position, low debt, and significant long-term upside potential despite current macroeconomic challenges. The company's fundame
Here is an emphasis on the importance of diversification in US-based investment portfolios to mitigate risks and enhance returns. The recommendation is to focus on sectors with strong growth potential
Carl Zeiss Meditec has seen a 30%+ decline due to earnings and margin drops, but remains a strong market leader with significant long-term upside. Despite current underperformance, the company's strat
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE